Combined effects of IL-8 and CXCR2 gene polymorphisms on breast cancer susceptibility and aggressiveness

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Snoussi, Kaouther ^a   Mahfoudh, Wijden ^a   Bouaouina, Noureddine ^a,b   Fekih, Meriem ^b   Khairi, Hedi ^b   Helal, Ahmed N ^c   Chouchane, Lotfi ^a,d  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b FARHAT HACHED HOSPITAL   (Tunisia)

^c UNIVERSITY OF MONASTIR   (Tunisia)

^d WEILL CORNELL MEDICAL COLLEGE   (Qatar)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; CHEMOKINE RECEPTOR CXCR2; INTERLEUKIN 8; THYMINE; IL8 PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER RISK; CANCER SIZE; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DNA POLYMORPHISM; FEMALE; GENETIC MARKER; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOTE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PHENOTYPE; POLYMERASE CHAIN REACTION; PROGNOSIS; TUNISIA; AGED; BREAST TUMOR; CANCER INVASION; CANCER STAGING; CARCINOMA; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TIME;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-8; KAPLAN-MEIERS ESTIMATE; LOGISTIC MODELS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; ODDS RATIO; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, INTERLEUKIN-8B; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TUNISIA; YOUNG ADULT;

EID: 77953307455     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-283     Document Type: Article

References (54)

1. American Cancer Society Facts and Figures 2005, American Cancer Society Facts and Figures., http://www.cancer.org
2. World Health Organization Facts and Figures World Health Organization Facts and Figures., http://www.who.int
3. Antoniou AC, Pharoah PD, McMullan G, Day NE, Ponder BA, Easton D. Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol 2001, 21:1-18. 10.1002/gepi.1014, 11443730.
4. Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 1998, 338(7):436-45. 10.1056/NEJM199802123380706, 9459648.
5. Rollins BJ. Chemokines. Blood 1997, 90:909-28.
6. Strieter RM, Burdick MD, Gomperts BN, Belperio JA, Keane MP. CXC chemokines in angiogenesis. Cytokine Growth Factor Rev 2005, 16:593-609. 10.1016/j.cytogfr.2005.04.007, 16046180.
7. Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J. The functionnal role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995, 270:27348-57. 10.1074/jbc.270.45.27348, 7592998.
8. Strieter RM, Belperio JA, Roderick JP, Keane MP. CXC chemokines in angiogenesis of cancer. Semin Cancer Biol 2004, 14:195-200. 10.1016/j.semcancer.2003.10.006, 15246055.
9. Matsushima K, Baldwin ET, Mukaida N. Interleukin-8 and MCAF: novel leukocyte recruitment and activity cytokines. Chem Immunol 1992, 51:236-265.
10. Inoue K, Slaton JW, Kim SJ, Perrotte P, Eve BY, Bar-Eli M, Radinsky R, Dinney CP. IL-8 expression regulates tumorigenecity and metastasis in human bladder cancer. Cancer Res 2000, 60:2290-99.
11. Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Dinney CPN. Interleukin 8 expression regulates tumorigenecity and metastases in androgen-independent prostate cancer. Clin Cancer Res 2000, 6:2104-19.
12. Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 2001, 2:375-91.
13. Araki S, Omori Y, Lyn D, Singh RK, Meinbach DM, Sandman Y, Lokeshwar VB, Lokeshwar BL. Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res 2007, 67(14):6854-62. 10.1158/0008-5472.CAN-07-1162, 17638896.
14. Ahmed OI, Adel AM, Diab DR, Gobran NS. Prognostic value of serum level of interleukin-6 and interleukin-8 in metastatic breast cancer patients. Egypt J Immunol 2006, 13(2):61-8.
15. Millar HJ, Nemeth JA, McCabe FL, Pikounis B, Wickstrom E. Circulating human interleukin-8 as an indicator of cancer progression in a nude rat orthotopic human non-small cell lung carcinoma model. Cancer Epidemiol Biomarkers Prev 2008, 17(8):2180-87. 10.1158/1055-9965.EPI-07-2915, 18708412.
16. Taguchi A, Ohmiya N, Shirai K, Mabuchi N, Itoh A, Hirooka Y, Niwa Y, Goto H. Interleukin-8 promoter polymorphism increases the risk of atrophic gastritis and gastric cancer in Japan. Cancer Epidemiol Biomarkers Prev 2005, 14(11):2487-93. 10.1158/1055-9965.EPI-05-0326, 16284368.
17. Murphy PM. The molecular biology of leucocytes chemoattractant receptors. Annu Rev Immuno 1994, 12:593-633.
18. Addison CL, Daniel TO, Burdick MD, Liu H, Ehlert JE, Xue YY, Buechi L, Walz A, Richmond A, Strieter RM. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J Immunol 2000, 165(9):5269-77.
19. Murdoch C, Monk PN, Finn A. Chemokine receptor expression on human endothelial cells. Cytokine 1999, 11:704-12. 10.1006/cyto.1998.0465, 10479407.
20. Miller LJ, Kurtzman SH, Wang Y, Anderson KH, Lindquist RR, Kreutzer DL. Expression of interleukin-8 receptors on tumor cells and vascular endothelial cells in human breast cancer tissue. Anticancer Res 1998, 18:77-81.
21. Bidwell J, Keen L, Gallagher G, Kimberly R, Huizinga T, McDermott MF. Cytokine gene polymorphism in human disease: on-line databases, supplement 1. Genes Immun 2001, 2:61-70. 10.1038/sj.gene.6363733, 11393658.
22. Mukaida N, Shiroo M, Matsushima K. Genomic structure of the human monocyte-derived neutrophil chemotactic factor IL-8. J Immunol 1989, 143:1366-71.
23. Hull J, Thompson A, Kwiatkowski D. Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax 2000, 55:1023-27. 10.1136/thorax.55.12.1023, 1745668, 11083887.
24. Lurje G, Zhang W, Schultheis AM, Yang D, Groshen S, Hendifar AE, Husain H, Gordon MA, Nagashima F, Chang HM, Lenz HJ. Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Ann Oncol 2008, 19(10):1734-41. 10.1093/annonc/mdn368, 2735064, 18550579.
25. Ohyauchi M, Imatani A, Yonechi M, Asano N, Miura A, Iijima K, Koike T, Sekine H, Ohara S, Shimosegawa T. The polymorphism interleukin 8 -251 A/T influences the susceptibility of Helicobacter pylori related gastric diseases in the Japanese population. Gut 2005, 54:330-35. 10.1136/gut.2003.033050, 1774396, 15710978.
26. McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A, Southgate C, Easton DF, Eeles RA, Howell WM. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 2002, 62(12):3369-72.
27. Ben Nasr H, Chahed K, Mestiri S, Bouaouina N, Snoussi K, Chouchane L. Association of IL-8 (-251) T/A polymorphism with susceptibility to and aggressiveness of nasopharyngeal carcinoma. Hum Immunol 2007, 68:761-69. 10.1016/j.humimm.2007.06.006, 17869651.
28. Renzoni E, Lympany P, Sestini P. Distribution of novel polymorphisms of IL-8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. Arthritis Rheum 2000, 43:1633-40. 10.1002/1529-0131(200007)43:7<1633::AID-ANR29>3.0.CO;2-9, 10902769.
29. Barnes PJ. Genetics and pulmonary medicine: 9. Molecular genetics of chronic obstructive pulmonary disease. Thorax 1999, 54:245-52. 10.1136/thx.54.3.245, 1745439, 10325902.
30. Snoussi K, Mahfoudh W, Bouaouina N, Helal AN, Chouchane L. Genetic variation in IL-8 associated with increased risk and poor prognosis of breast carcinoma. Hum Immunol 2006, 67:13-21. 10.1016/j.humimm.2006.03.018, 16698420.
31. Ben Ahmed S, Aloulou S, Bibi M, Landolsi A, Nouira M, Ben Fatma L, Kallel L, Gharbi O, Khairi H, Kraiem C. Breast cancer detection in Tunisian women: an analysis of a hospital trial involving 729 patients. Santé Publique 2002, 14:231-35.
32. Olerup O, Zetterquiest H. HLA-DR typing by PCR amplification with sequence specific primers (PCR-SSP) in two hours: an alternative to serological DR typing in clinical practice including donor recipient matching in cadaveric transplantation. Tissue Antigens 1992, 39:225-29. 10.1111/j.1399-0039.1992.tb01940.x, 1357775.
33. Kaplan EL, Meir PO. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-61.
34. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. Br J Cancer 1977, 35:1-6. 2025310, 831755.
35. Cox DR, McCullagh P. Some aspects of analysis of covariance. Biometrics 1982, 38:541-61. 10.2307/2530040, 7171689.
36. Heidemann J, Ogawa H, Dwinell MB, Rafiee P, Maaser C, Gockel HR. Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR-2. J Biol Chem 2003, 278:8508-15. 10.1074/jbc.M208231200, 12496258.
37. Mestas J, Burdick MD, Reckamp K, Pantuck A, Figlin RA, Streiter RM. The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma. J Immunol 2005, 175(8):5351-57.
38. Murphy C, McGurk M, Pettigrew J, Santinelli A, Mazzucchelli R, Johnston PG, Montironi R, Waugh DJ. Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. Clin Cancer Res 2005, 11:4117-27. 10.1158/1078-0432.CCR-04-1518, 15930347.
39. Wente MN, Keane MP, Burdick MD, Friess H, Büchler MW, Ceyhan GO, Reber HA, Strieter RM, Hines OJ. Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis. Cancer Lett 2006, 241(2):221-7. 10.1016/j.canlet.2005.10.041, 16458421.
40. Li A, Varney ML, Singh RK. Expression of interleukin 8 and its receptors in human colon carcinoma cells with different metastatic potentials. Clin Cancer Res 2001, 7(10):3298-304.
41. Horikawa T, Kaizaki Y, Kato H, Furukawa M, Yoshizaki T. Expression of interleukin-8 receptor A predicts poor outcome in patients with nasopharyngeal carcinoma. Laryngoscope 2005, 115(1):62-7. 10.1097/01.mlg.0000150675.37860.f7, 15630368.
42. Benoy IH, Salgado R, Van Dam P, Geboers K, Van Marck E, Scharpé S, Vermeulen PB, Dirix LY. Increased serum interleukin-8 patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res 2004, 10:7157-62. 10.1158/1078-0432.CCR-04-0812, 15534087.
43. Ben-Baruch A. Inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Res 2003, 5:31-36. 10.1186/bcr554, 154133, 12559043.
44. Savage SA, Abnet CC, Mark SD, Qiao YL, Dong ZW, Dawsey SM, Taylor PR, Chanock SJ. Variants of the IL8 and IL8RB genes and risk for gastric cardia adenocarcinoma and esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2004, 13(12):2251-57.
45. Kamali-Sarvestani E, Aliparasti MR, Atefi S. Association of interleukin-8 (IL-8 or CXCL8) -251T/A and CXCR2 +1208C/T gene polymorphisms with breast cancer. Neoplasma 2007, 54(6):484-9.
46. Danahue TR, Hines OJ. CXCR2 and RET single nucleotide polymorphisms in pancreatic cancer. World J Surg 2009, 33(4):710-15. 10.1007/s00268-008-9826-z, 19057948.
47. Yang HP, Woodson K, Taylor PR, Pietinen P, Albanes D, Virtamo J, Tangrea JA. Genetic variation in interleukin 8 and its receptor genes and its influence on the risk and prognosis of prostate cancer amon Finnish men in a large cancer prevention trial. Eur J Cancer Prev 2006, 15(3):249-53. 10.1097/01.cej.0000199504.07947.e7, 16679868.
48. Morohashi H, Miyawaki T, Nomura H, Kuno K, Murakami S, Matsushima K, Mukaida N. Expression of both types of human interleukin-8 receptors on mature neutrophiles, monocytes, and natural killer cells. J Leukoc Biol 1995, 57:180-87.
49. Li A, Dubey S, Varney ML, Dave BJ, Singh RK. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003, 170:3369-76.
50. Ren Y, Tung-Ping Poon R, Tsui H, Chen WH, Zhi L, Lau C. Interleukin-8 Serum Levels in Patients with Hepatocellular Carcinoma: Correlations with Clinicopathological Features and Prognosis. Clin Cancer Res 2003, 9:5996-6001.
51. Freund A, Chauveau C, Brouillet JP, Lucas A, Lacroix M, Licznar A, Vignon F, Lazennec G. IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells. Oncogene 2003, 22(2):256-65. 10.1038/sj.onc.1206113, 2034407, 12527894.
52. Singh S, Varney M, Singh RK. Host CXCR2-dependent regulation of melanoma growth, angiogenesis, and experimental lung metastasis. Cancer Res 2009, 69(2):411-5. 10.1158/0008-5472.CAN-08-3378, 2652477, 19147552.
53. Salcedo R, Resau JH, Halverson D, Hudson EA, Dambach M, Powell D, Wasserman K, Oppenheim JJ. Differential expression and responsiveness of chemokine receptors (CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells. FASEB J 2000, 14(13):2055-64. 10.1096/fj.99-0963com, 11023990.
54. Keane MP, Belperio JA, Xue YY, Burdick MD, Strieter RM. Depletion of CXCR-2 Inhibits Tumor Growth and angiogenesis in a murine model of lung cancer. Journal of Immunology 2004, 172:2853-2860.